Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc.
Your view on XERS
Overview
What the company does, where it operates, and who runs it.
About Xeris Biopharma Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John P. Shannon
- Headquarters
- 180 North LaSalle Street, Chicago, IL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John P. Shannon
- Headquarters
- 180 North LaSalle Street, Chicago, IL, US
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.
The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Xeris Biopharma Holdings, Inc., and the rating behind it. XERS last traded at $7.45; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Xeris Biopharma Holdings, Inc.. Starting points for Xeris Biopharma Holdings, Inc.: EPS -$0.10, beta 0.85 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Xeris Biopharma Holdings, Inc.. Xeris Biopharma Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Xeris Biopharma Holdings, Inc.. Trailing twelve-month EPS for Xeris Biopharma Holdings, Inc. stands at -$0.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Xeris Biopharma Holdings, Inc.. Xeris Biopharma Holdings, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Xeris Biopharma Holdings, Inc. valued side by side against its closest peers. Xeris Biopharma Holdings, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Xeris Biopharma Holdings, Inc., and how their positions are changing. At a $1.29B market value, institutional positions materially move Xeris Biopharma Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Xeris Biopharma Holdings, Inc. executives and directors. Shares of Xeris Biopharma Holdings, Inc. have traded between $2.96 and $10.08 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Xeris Biopharma Holdings, Inc.. Xeris Biopharma Holdings, Inc. is a $1.29B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Xeris Biopharma Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Xeris Biopharma Holdings, Inc.. Coverage tracks Xeris Biopharma Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.